Effectiveness of the 2023-2024 monovalent XBB.1.5 vaccine against SARS-CoV-2 infection in people aged over 65 years in South Korea: a population-based cohort study

Objectives: The continued emergence of SARS-CoV-2 variants, including XBB.1.5 and its sublineages, poses challenges for COVID-19 control, particularly in high-risk populations. This study evaluated the community-based effectiveness of the 2023-2024 monovalent XBB.1.5 vaccine in preventing SARS-CoV-2...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Suyoung Jo, Seunghyun Lee, Huiseon Kim, Hyunji Won, Gi-eun Rhie, Hye-Sook Jeong, June-Woo Lee, Ah-Ra Kim, Byung Chul Chun, Kyong Ran Peck, Dong-Hyun Kim
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2026-02-01
Цуврал:	International Journal of Infectious Diseases
Нөхцлүүд:	COVID-19 Vaccine effectiveness K-SEROSMART Population-based cohort study Nested case-control study
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S1201971225004606
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!